NASDAQ:TRIB - Trinity Biotech Stock Price, Price Target & More

$5.00 +0.11 (+2.25 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$5.00

Today's Range$4.82 - $5.00

52-Week Range$4.22 - $6.54

Volume14,172 shs

Average Volume26,466 shs

Market Capitalization$117.56 million

P/E Ratio19.23

Dividend YieldN/A

Beta1.31

About Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. Further, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:TRIB

CUSIPN/A

Webwww.trinitybiotech.com

Phone353-1276-9800

Debt

Debt-to-Equity Ratio1.45%

Current Ratio5.30%

Quick Ratio3.76%

Price-To-Earnings

Trailing P/E Ratio19.23

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$99.14 million

Price / Sales1.21

Cash Flow$0.4798 per share

Price / Cash10.42

Book Value$2.71 per share

Price / Book1.85

Profitability

EPS (Most Recent Fiscal Year)$0.26

Net Income$2.30 million

Net Margins-40.62%

Return on Equity2.37%

Return on Assets0.99%

Miscellaneous

Employees582

Outstanding Shares24,040,000

How to Become a New Pot Stock Millionaire

Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech's earnings last quarter?

Trinity Biotech (NASDAQ:TRIB) issued its quarterly earnings data on Wednesday, March, 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.01. The firm had revenue of $24.55 million for the quarter, compared to analyst estimates of $23.53 million. Trinity Biotech had a negative net margin of 40.62% and a positive return on equity of 2.37%. View Trinity Biotech's Earnings History.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Trinity Biotech.

Who are some of Trinity Biotech's key competitors?

Some companies that are related to Trinity Biotech include Vision Sciences (CGNT), Melinta Therapeutics (MLNT), Ardelyx (ARDX), Viking Therapeutics (VKTX), ChromaDex (CDXC), Calithera Biosciences (CALA), Allergy Therapeutics (AGYTF), Fluidigm (FLDM), CRH Medical (CRHM), Synlogic (SYBX), Cytosorbents (CTSO), Aratana Therapeutics (PETX), CTI BioPharma (CTIC), Corvus Pharmaceuticals (CRVS), Recro Pharma (REPH), Arsanis (ASNS), Fortress Biotech (FBIO) and Verona Pharma (VRNA).

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the folowing people:

Mr. Ronan O'Caoimh, Co-Founder, Chairman and Chief Exec. Officer (Age 62)
Mr. Kevin Tansley, Chief Financial Officer, Sec. and Director (Age 47)
Dr. James Walsh Ph.D., Bus. Devel. Director and Exec. Director (Age 60)

Has Trinity Biotech been receiving favorable news coverage?

Headlines about TRIB stock have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trinity Biotech earned a daily sentiment score of 0.13 on Accern's scale. They also gave press coverage about the company an impact score of 46.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include LAPIDES ASSET MANAGEMENT, LLC (5.00%) and LAPIDES ASSET MANAGEMENT, LLC (5.00%). View Institutional Ownership Trends for Trinity Biotech.

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $5.00.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $117.56 million and generates $99.14 million in revenue each year. The company earns $2.30 million in net income (profit) each year or $0.26 on an earnings per share basis. Trinity Biotech employs 582 workers across the globe.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]

MarketBeat Community Rating for Trinity Biotech (TRIB)

Community Ranking:		2.2 out of 5 ( )
Outperform Votes:		107 (Vote Outperform)
Underperform Votes:		141 (Vote Underperform)
Total Votes:		248

MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Trinity Biotech (NASDAQ:TRIB) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	N/A	N/A	N/A
Consensus Rating Score:	N/A	N/A	N/A	N/A
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Trinity Biotech (NASDAQ:TRIB) Consensus Price Target History

Price Target History for Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech (NASDAQ:TRIB) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
10/5/2016	Stephens	Downgrade	Overweight -> Equal Weight		N/A
4/21/2016	Roth Capital	Reiterated Rating	Buy		N/A

(Data available from 4/21/2016 forward)

Trinity Biotech (NASDAQ:TRIB) Earnings History and Estimates Chart

Earnings by Quarter for Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech (NASDAQ TRIB) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/25/2018		$0.06					N/A
3/7/2018	Not Specified	$0.07	$0.08	$23.53 million	$24.55 million	View	Listen
10/26/2017	9/30/2017	$0.03	$0.06	$25.52 million	$25.60 million	View	N/A
7/20/2017	6/30/2017	$0.06	$0.03	$24.83 million	$25.45 million	View	N/A
4/27/2017	3/31/2017	$0.03	$0.01	$24.24 million	$23.54 million	View	N/A
10/25/2016	Q3	$0.07	$0.07	$26.50 million	$26.10 million	View	Listen
7/21/2016	Q2	$0.06	$0.0850	$24.30 million	$26.30 million	View	Listen
4/19/2016	Q1	$0.08	$0.0640	$24.34 million	$23.52 million	View	Listen
3/3/2016	Q4	$0.09	$0.29	$251.00 million	$271.20 million	View	N/A
10/22/2015	Q3	$0.09	$0.10	$25.40 million	$27.20 million	View	Listen
7/28/2015	Q2	$0.14	$0.07	$26.09 million	$24.26 million	View	Listen
4/30/2015	Q115	$0.17	$0.17	$25.93 million	$25.20 million	View	N/A
3/3/2015	Q414	$0.18	$0.18	$27.30 million	$26.70 million	View	N/A
10/23/2014	Q114	$0.20	$0.19	$27.30 million	$27.20 million	View	Listen
7/29/2014	Q413	$0.20	$0.18	$27.00 million	$26.00 million	View	N/A
4/29/2014		$0.19	$0.18	$25.48 million	$25.03 million	View	N/A
3/4/2014	Q4	$0.21	$0.20	$25.79 million	$25.46 million	View	N/A
10/17/2013	Q313	$0.21	$0.21	$24.68 million	$24.10 million	View	N/A
7/30/2013	Q2 2013	$0.20	$0.21	$22.03 million	$21.30 million	View	N/A
4/25/2013	Q1 2013	$0.19	$0.19	$21.20 million	$20.33 million	View	N/A
3/5/2013	Q4 2012	$0.21	$0.20	$21.84 million	$20.80 million	View	N/A
10/18/2012	Q3 2012	$0.20	$0.20			View	N/A
7/12/2012	Q2 2012	$0.19	$0.19			View	N/A
4/19/2012	Q1 2012	$0.17	$0.19			View	N/A
3/5/2012	Q4 2011	$0.19	$0.18			View	N/A
10/20/2011	Q3 2011	$0.17	$0.18			View	N/A
7/21/2011	Q2 2011	$0.16	$0.17			View	N/A
5/5/2011	Q1 2011	$0.15	$0.17			View	N/A
3/3/2011	Q4 2010	$0.14	$0.17			View	N/A
10/20/2010	Q3 2010	$0.14	$0.16			View	N/A
7/29/2010	Q2 2010	$0.14	$0.16			View	N/A
5/11/2010	Q1 2010	$0.12	$0.15			View	N/A
3/11/2010	Q4 2009	$0.13	$0.15			View	N/A
10/21/2009	Q3 2009	$0.12	$0.15			View	N/A
7/23/2009	Q2 2009	$0.10	$0.14			View	N/A
4/29/2009	Q1 2009	$0.07	$0.12			View	N/A
3/10/2009	Q4 2008	$0.03	$0.08			View	N/A
10/31/2008	Q3 2008	$0.08	$0.06			View	N/A
7/22/2008	Q2 2008	$0.08	$0.07			View	N/A
4/29/2008	Q1 2008	$0.04	$0.06			View	N/A
3/14/2008	Q4 2007	$0.10	$0.06			View	N/A

(Earnings results data provided by Zacks Investment Research)

Trinity Biotech (NASDAQ:TRIB) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/23/2014	annual	$0.22	3.72%	6/6/2014	6/10/2014	7/1/2014

(Data available from 1/1/2013 forward)

Trinity Biotech (NASDAQ TRIB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.70%
Institutional Ownership Percentage: 62.08%

Insider Trading History for Trinity Biotech (NASDAQ:TRIB)

Institutional Ownership by Quarter for Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech (NASDAQ TRIB) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Trinity Biotech (NASDAQ TRIB) News Headlines

Source:

Date	Headline
	Critical Review: Trinity Biotech (TRIB) versus Its Peers www.americanbankingnews.com - April 21 at 1:18 PM
	Trinity Biotech (TRIB) Downgraded by ValuEngine to Strong Sell www.americanbankingnews.com - April 21 at 7:06 AM
	Trinity Biotech plc to Announce First Quarter Fiscal Year 2018 Financial Results finance.yahoo.com - April 20 at 5:26 PM
	Trinity Biotech (TRIB) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 4:38 AM
	Contrasting Trinity Biotech (TRIB) & Its Peers www.americanbankingnews.com - April 17 at 9:23 AM
	Trinity Biotech (TRIB) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 16 at 1:54 PM
	Comparing Trinity Biotech (TRIB) and Its Rivals www.americanbankingnews.com - April 15 at 7:21 AM
	Critical Comparison: Trinity Biotech (TRIB) vs. Its Competitors www.americanbankingnews.com - April 13 at 7:19 PM
	Trinity Biotech (TRIB) Cut to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 13 at 11:23 AM
	Trinity Biotech (TRIB) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 12 at 10:18 PM
	Financial Review: Trinity Biotech (TRIB) versus Its Rivals www.americanbankingnews.com - April 10 at 5:18 PM
	Trinity Biotech (TRIB) versus The Competition Critical Analysis www.americanbankingnews.com - April 8 at 1:17 AM
	Critical Comparison: Trinity Biotech (TRIB) and Its Peers www.americanbankingnews.com - April 7 at 7:31 AM
	Trinity Biotech (TRIB) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - April 5 at 4:06 PM
	Trinity Biotech (TRIB) & Its Competitors Critical Review www.americanbankingnews.com - April 5 at 9:49 AM
	Reviewing Trinity Biotech (TRIB) & Its Competitors www.americanbankingnews.com - April 3 at 5:17 AM
	Edited Transcript of TRIB earnings conference call or presentation 7-Mar-18 4:00pm GMT finance.yahoo.com - March 18 at 8:12 AM
	Zacks Investment Research Downgrades Trinity Biotech (TRIB) to Sell www.americanbankingnews.com - March 13 at 3:57 PM
	Trinity Biotech announces Quarter 4 and Fiscal Year 2017 Financial Results finance.yahoo.com - March 7 at 6:40 PM
	Trinity Biotech (TRIB) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - March 7 at 1:25 PM
	Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2017 Financial Results finance.yahoo.com - March 5 at 5:54 PM
	Trinity Biotech (TRIB) Scheduled to Post Earnings on Monday www.americanbankingnews.com - March 5 at 2:34 AM
	Senvest Management LLC Raises Holdings in Trinity Biotech plc (TRIB) www.americanbankingnews.com - February 26 at 11:36 AM
	Adirondack Research & Management Inc. Increases Holdings in Trinity Biotech plc (TRIB) www.americanbankingnews.com - February 26 at 5:10 AM
	Depth Filtration Market to Reach US$ 3 Billion By 2022 www.marketwatch.com - February 23 at 8:15 AM
	ValuEngine Downgrades Trinity Biotech (TRIB) to Sell www.americanbankingnews.com - February 4 at 11:46 AM
	Trinity Biotech (TRIB) Upgraded to Hold by Zacks Investment Research www.americanbankingnews.com - February 2 at 7:48 PM
	Trinity Biotech (TRIB) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - January 25 at 6:58 PM
	Trinity Biotech (TRIB) Upgraded to Hold at Zacks Investment Research www.americanbankingnews.com - December 28 at 9:28 PM
	Trinity Biotech Plc: Gathering momentum, but may lack support finance.yahoo.com - December 12 at 3:43 PM
	Zacks Investment Research Lowers Trinity Biotech PLC (TRIB) to Strong Sell www.americanbankingnews.com - November 1 at 11:56 AM
	Trinity Biotech Plc :TRIB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 finance.yahoo.com - November 1 at 9:49 AM
	Edited Transcript of TRIB earnings conference call or presentation 26-Oct-17 3:00pm GMT finance.yahoo.com - October 27 at 7:02 AM
	Trinity Biotech PLC (TRIB) Announces Quarterly Earnings Results www.americanbankingnews.com - October 26 at 9:06 PM
	Trinity Biotech Announces Results for Q3, 2017 finance.yahoo.com - October 26 at 9:34 AM
	Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call finance.yahoo.com - October 26 at 9:34 AM
	Trinity Biotech PLC (TRIB) Scheduled to Post Earnings on Monday www.americanbankingnews.com - October 16 at 3:50 AM
	Trinity Biotech plc to Announce 2017 Third Quarter Financial Results feeds.benzinga.com - October 13 at 5:19 AM
	INVESTOR ALERT: Kirby McInerney LLP Commences Investigation on Behalf of Trinity Biotech plc Investors finance.yahoo.com - August 11 at 8:57 AM
	Trinity Biotech Plc :TRIB-US: Earnings Analysis: Q2, 2017 By the Numbers : July 26, 2017 finance.yahoo.com - July 27 at 8:37 AM
	Trinity Biotech PLC (TRIB) Issues Quarterly Earnings Results www.americanbankingnews.com - July 21 at 11:05 AM
	Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call www.baystreet.ca - July 21 at 8:01 AM
	Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call www.baystreet.ca - July 21 at 8:01 AM
	Edited Transcript of TRIB earnings conference call or presentation 20-Jul-17 3:00pm GMT finance.yahoo.com - July 21 at 8:01 AM
	Edited Transcript of TRIB earnings conference call or presentation 20-Jul-17 3:00pm GMT finance.yahoo.com - July 21 at 8:01 AM
	Head-To-Head Survey: Trinity Biotech PLC (TRIB) & DBV Technologies (DBVT) www.americanbankingnews.com - July 20 at 9:16 AM
	Trinity Biotech PLC (NASDAQ:TRIB) vs. DBV Technologies (DBVT) Head-To-Head Survey www.americanbankingnews.com - July 20 at 9:15 AM
	Trinity Biotech Announces Results for Q2, 2017 finance.yahoo.com - July 20 at 8:51 AM
	Contrasting Trinity Biotech PLC (TRIB) & DBV Technologies (DBVT) www.americanbankingnews.com - July 18 at 12:27 AM
	Trinity Biotech PLC (TRIB) Set to Announce Earnings on Thursday www.americanbankingnews.com - July 13 at 10:08 PM

Trinity Biotech (NASDAQ:TRIB) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Trinity Biotech (NASDAQ:TRIB) Income Statement, Balance Sheet and Cash Flow Statement

Trinity Biotech (NASDAQ TRIB) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff